-
Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital
Thursday, July 13, 2023 - 3:48pm | 439Read More...Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital (MGH) on the effects of psilocybin-assisted psychotherapy for adults with...
-
Therapists At Mass General Hospital Prepared To Assist IBS Patients With Psilocybin Therapy
Tuesday, April 4, 2023 - 4:47pm | 356Read More...Psychotherapists at the Massachusetts General Hospital (MGH) have undergone training by lead business Fluence toward participating in Tryp Therapeutics (OTCQB: TRYPF)’ Phase 2a trial assessing psilocybin-assisted psychotherapy on adult participants with treatment-resistant Irritable Bowel...
-
Can Marijuana Treat Autism, OCD & Irritable Bowel Syndrome? Ohio Medical Panel Will Investigate
Monday, February 13, 2023 - 1:16pm | 656Read More...Ohio researchers want to learn more about the effects of medical marijuana on those with autism spectrum disorder (ASD), obsessive-compulsive disorder (OCD) and irritable bowel syndrome, reported Cleveland.com. Last week, the State Medical Board began researching whether these...
-
Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients
Tuesday, January 3, 2023 - 3:50pm | 540Read More...Psychedelics company Tryp Therapeutics Inc. (OTCQB: TRYPF) and Harvard’s largest medical teaching facility, the Massachusetts General Hospital (MGH) have inked a Letter of Intent (LOI) to fund and conduct a Phase 2a clinical trial assessing the effects of psilocybin-assisted...
-
Silo Wellness To Acquire Canadian Dyscovry Science, Producer Of Psilocybin For IBS Treatment
Tuesday, May 31, 2022 - 3:43pm | 358Read More...Silo Wellness (SILFF), a growth-oriented holding company focused on functional mushroom and psychedelic opportunities, has presented a nonbinding letter of intent to fully acquire Dyscovry Science Ltd. The Toronto-based biotech Dyscovry is involved in the biosynthetic...
-
Biomerica Posts Encouraging Results From InFoods Study As Irritable Bowel Syndrome Treatment
Tuesday, February 8, 2022 - 1:27pm | 308Read More...Biomerica Inc (NASDAQ: BMRA) has announced topline results from its InFoods IBS diagnostic-guided therapy (DGT) endpoint clinical trial. The trial showed statistically significant improvements in multiple endpoints in the Intent-to-Treat population. The InFoods DGT uses a...
-
Citi, Ladenburg React Positively On Ardelyx's IBS-C Treatment Launch Plans
Wednesday, December 1, 2021 - 8:38am | 362Read More...Citigroup raised the price target on Ardelyx Inc (NASDAQ: ARDX) to $13 from $7, with a Buy rating unchanged. The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022....
-
4D Pharma's Stock Shoots Higher on Positive Data from Irritable Bowel Syndrome Candidate
Monday, May 24, 2021 - 9:30am | 360Read More...4D pharma plc (NASDAQ: LBPS) has announced additional positive data from its completed Phase 2 trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D). The data has been presented at Digestive Disease Week (DDW). The company...
-
Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain
Wednesday, March 3, 2021 - 7:10am | 266Read More...Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for abdominal pain due to Irritable Bowel Syndrome (IBS). Although olorinab was well tolerated, the results show that it did not meet the primary...
-
Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike
Thursday, February 18, 2021 - 10:27am | 264Read More...Hoth Therapeutics Inc (NASDAQ: HOTH) plans to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis. The company has...
-
Synthetic Biologics Surges 25% Amid Positive Phase 2 Data
Wednesday, January 20, 2016 - 9:22am | 252Read More...Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, surged higher by 25 percent at $1.90 early Wednesday morning after the company reported positive topline data from a second Phase 2 clinical trial. Synthetic Biologics stated that its second Phase 2 clinical...
